JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Search

AbbVie Inc

Fermé

SecteurSoins de santé

198.07 -0.35

Résumé

Variation du prix de l'action

24h

Actuel

Min

198

Max

198.64

Chiffres clés

By Trading Economics

Revenu

1.3B

1.3B

Ventes

2.1B

15B

P/E

Moyenne du Secteur

92.578

34.393

BPA

2.97

Rendement du dividende

3.31

Marge bénéficiaire

9.66

Employés

55,000

EBITDA

-4.3B

117M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+9.3% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.31%

2.54%

Prochains Résultats

29 oct. 2025

Date du Prochain Dividende

15 août 2025

Date du Prochain Détachement de Dividende

14 oct. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

12B

348B

Ouverture précédente

198.42

Clôture précédente

198.07

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

AbbVie Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

31 juil. 2025, 12:46 UTC

Résultats

AbbVie 2Q Results Top Wall Street's Forecasts with Boost from Skyrizi, Rinvoq Sales

30 juin 2025, 13:02 UTC

Acquisitions, Fusions, Rachats

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion in Cash

25 avr. 2025, 13:57 UTC

Résultats

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update

25 avr. 2025, 12:52 UTC

Résultats

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised

31 juil. 2025, 12:08 UTC

Résultats

AbbVie Stock Pops After Earnings Beat and Guidance Raised -- Barrons.com

31 juil. 2025, 11:46 UTC

Résultats

AbbVie Raises FY Outlook

31 juil. 2025, 11:44 UTC

Résultats

AbbVie 2Q Global Net Rev From Oncology Portfolio $1.68B >ABBV

31 juil. 2025, 11:44 UTC

Résultats

AbbVie 2Q Global IMBRUVICA Rev $754M >ABBV

31 juil. 2025, 11:44 UTC

Résultats

AbbVie 2Q Global Skyrizi Rev $4.42B >ABBV

31 juil. 2025, 11:44 UTC

Résultats

AbbVie 2Q Adj EPS $2.97 >ABBV

31 juil. 2025, 11:44 UTC

Résultats

AbbVie 2Q U.S. HUMIRA Rev $802M >ABBV

31 juil. 2025, 11:44 UTC

Résultats

AbbVie Sees FY Adj EPS $11.88-Adj EPS $12.08 >ABBV

31 juil. 2025, 11:44 UTC

Résultats

AbbVie 2Q EPS 52c >ABBV

31 juil. 2025, 11:44 UTC

Résultats

AbbVie 2Q Rev $15.42B >ABBV

31 juil. 2025, 11:44 UTC

Résultats

AbbVie 2Q International HUMIRA Rev $378M >ABBV

31 juil. 2025, 11:44 UTC

Résultats

AbbVie 2Q Net $938M >ABBV

30 juin 2025, 12:47 UTC

Acquisitions, Fusions, Rachats

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1B in Cash

30 juin 2025, 12:33 UTC

Acquisitions, Fusions, Rachats

AbbVie Will Acquire Capstan, Including CPTX2309, a Potential First-In-Class in Vivo tLNP anti-CD19 CAR-T Therapy Candidate >ABBV

30 juin 2025, 12:33 UTC

Acquisitions, Fusions, Rachats

AbbVie : Proposed Acquisition Strengthens Commitment to Transforming Patient Care With Capstan's Innovative tLNP Platform Technology >ABBV

30 juin 2025, 12:32 UTC

Acquisitions, Fusions, Rachats

AbbVie Will Pay Up to $2.1B in Cash at Closing to Acquire Capstan >ABBV

30 juin 2025, 12:31 UTC

Acquisitions, Fusions, Rachats

AbbVie To Acquire Capstan Therapeutics, Further Strengthening Commitment To Transforming Patient Care In Immunology >ABBV

7 mai 2025, 09:30 UTC

Actualités

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

28 avr. 2025, 12:44 UTC

Résultats

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

28 avr. 2025, 09:33 UTC

Résultats

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 avr. 2025, 16:03 UTC

Résultats

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 avr. 2025, 14:00 UTC

Actualités
Résultats

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 avr. 2025, 12:24 UTC

Actualités
Résultats

AbbVie Stock Jumps as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 avr. 2025, 12:03 UTC

Actualités
Résultats

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 avr. 2025, 11:43 UTC

Résultats

AbbVie 1Q U.S. HUMIRA Rev $744M >ABBV

25 avr. 2025, 11:43 UTC

Résultats

AbbVie 1Q International HUMIRA Rev $377M >ABBV

Comparaison

Variation de prix

AbbVie Inc prévision

Objectif de Prix

By TipRanks

9.3% hausse

Prévisions sur 12 Mois

Moyen 216.47 USD  9.3%

Haut 255 USD

Bas 170 USD

Basé sur 17 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

17 ratings

11

Achat

6

Maintien

0

Vente

Score Technique

By Trading Central

180.37 / 195.54Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.